SOURCE: Industry Standard Research

Industry Standard Research

April 26, 2016 10:30 ET

Sponsors Anticipate Considerable Growth in Outsourced Bioprocessing Over the Next Five Years

Informing the Pharmaceutical Drug Development, Manufacturing and Commercialization Industry

CARY, NC--(Marketwired - April 26, 2016) - A new report titled Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021, from Industry Standard Research (ISR), indicates considerable growth in the number of bioprocessing projects and the percentage of those projects that will be outsourced to CMOs over the next five years. Biologics have transformed the practice of medicine in a relatively short period of time due to their efficacy in treating complex diseases with fewer side effects than traditional small molecule drugs. As such, biopharmaceutical companies are focused on increasing the percentage of biologic-based drugs in their portfolios and pipelines.

"CMOs with bioprocessing capacity will be in increasing demand over the next five years as the annual average number of outsourced projects will increase from 8.2 to 14.3, according to research participants," explained Kate Hammeke, Director of Market Research at ISR. "Biopharma sponsors anticipate needing additional CMOs to meet their bioprocessing needs, not just additional capacity. This finding was reiterated among respondents who utilize a preferred provider list, as the number of preferred providers is also expected to grow."

In addition to findings on increased bioprocessing project volume, the report includes key statistics on utilization rates of the four main protein expression systems, the percentage of marketed biologics based off each development platform, which platforms are more likely to be outsourced, and a breakdown of annual outsourced expenditure by platform. The report also explores the types of biologics sponsor organizations currently have in development and on the market and the likelihood of outsourcing a bioprocessing project based on the type of biologic. Contract manufacturers can get a read on sponsors' familiarity with their large molecule offering and the likelihood of being considered for an outsourced bioprocessing project as well as which service provider attributes have the greatest impact on selection. 

CMOs included in the report are: AbbVie Contract Manufacturing, Aeras CMO, Althea, Avid Bioservices, Boehringer Ingelheim Bioexcellence, Catalent, Celltrion, CMC Biologics, Cobra Biologics, Cook Pharmica, Cytovance Biologics, Dalton Pharma Services, FujiFilm Diosynth Biotechnologies, GSK Contract Manufacturing, Hetero, IDT Biologika, KBI Biopharma, Kemwell, Lonza, Novasep, Paragon, Patheon, Pfizer CentreSource, Piramal Pharma Solutions, Rentschler, Richter-Helm, SAFC, Samsung BioLogics, Sandoz, Sanofi CEPiA, Therapure Biopharma, and Wuxi AppTec. 

This report provides insights into the bioprocessing market and where decision-makers at sponsor organizations think it is heading. These data will enable readers to make better decisions regarding outsourced bioprocessing.

For more information on ISR's "Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021" report, please visit ISR's report page at

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR's off-the-shelf intelligence and custom research offerings, please visit the company's website at, email or follow ISR on Twitter @ISRreports

Contact Information